Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation

Journal of Virology

Volumn 85, Issue 12, 2011, Pages 6060-6064

  Xing, Sifei ^a   Bullen, Cynthia K ^a   Shroff, Neeta S ^b   Shan, Liang ^a   Yang, Hung Chih ^a   Manucci, Jordyn L ^a   Bhat, Shridhar ^a   Zhang, Hao ^c   Margolick, Joseph B ^c   Quinn, Thomas C ^a,d   Margolis, David M ^e   Siliciano, Janet D ^a   Siliciano, Robert F ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^e UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIETHYLDITHIOCARBAMIC ACID; DISULFIRAM; GAMMA INTERFERON; GREEN FLUORESCENT PROTEIN; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 8; MESSENGER RNA; PROTEIN BCL 2; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CD4+ T LYMPHOCYTE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; GENE EXPRESSION; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; LATENT VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; VIRUS CELL INTERACTION; VIRUS LATENCY; VIRUS REACTIVATION; VIRUS RELEASE;

ANTI-HIV AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; DISULFIRAM; GENES, BCL-2; HIV INFECTIONS; HIV-1; HUMANS; LYMPHOCYTE ACTIVATION; PROTO-ONCOGENE PROTEINS C-BCL-2; TRANSDUCTION, GENETIC; VIRUS ACTIVATION; VIRUS LATENCY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 79958136377     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02033-10     Document Type: Article

References (16)

1. Archin, N. A., et al. 2008. Standard ART and valproic acid have limited impact on the persistence of HIV infection in resting CD4+ T cells. AIDS 22:1131-1135.
2. Brooks, D. G., et al. 2003. Molecular characterization, reactivation, and depletion of latent HIV. Immunity 19:413-423.
3. Chun, T. W., et al. 1997. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387:183-188.
4. Chun, T. W., et al. 1997. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc. Natl. Acad. Sci. U. S. A. 94:13193-13197.
5. Contreras, X., et al. 2009. Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. J. Biol. Chem. 284:6782-6789.
6. Faiman, M. D., J. C. Jensen, and R. B. Lacoursiere. 1984. Elimination kinetics of disulfiram in alcoholics after single and repeated doses. Clin. Pharmacol. Ther. 36:520-526.
7. Finzi, D., et al. 1997. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278:1295-1300.
8. Johansson, B. 1992. A review of the pharmacokinetics and pharmacodynamics of disulfiram and its metabolites. Acta Psychiatr. Scand. Suppl. 369:15-26.
9. McCance-Katz, E. F., T. R. Kosten, and P. Jatlow. 1998. Disulfiram effects on acute cocaine administration. Drug Alcohol Depend. 52:27-39.
10. Sauna, Z. E., S. Shukla, and S. V. Ambudkar. 2005. Disulfiram, an old drug with new potential therapeutic uses for human cancers and fungal infections. Mol. BioSyst. 1:127-134.
11. Siliciano, J. D., et al. 2003. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat. Med. 9:727- 728.
12. Towell, J. F., III, J. K. Cho, B. L. Roh, and R. I. Wang. 1983. Disulfiram and erythrocyte aldehyde dehydrogenase inhibition. Clin. Pharmacol. Ther. 33: 517-521.
13. Trono, D., et al. 2010. HIV persistence and the prospect of long-term drugfree remissions for HIV-infected individuals. Science 329:174-180.
14. Vaccari, A., P. L. Saba, S. Ruiu, M. Collu, and P. Devoto. 1996. Disulfiram and diethyldithiocarbamate intoxication affects the storage and release of striatal dopamine. Toxicol. Appl. Pharmacol. 139:102-108.
15. Wong, J. K., et al. 1997. Recovery of replication competent HIV despite prolonged suppression of plasma viremia. Science 278:1291-1295.
16. Yang, H. C., et al. 2009. Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation. J. Clin. Invest. 19:3473-3486.